


U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE		DATE: March 31, 2005
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. Application No. (if known) <b>10/529639</b>
INTERNATIONAL APPLICATION NO.: <b>PCT/JP2003/012575</b>	INTERNATIONAL FILING DATE: <b>October 1, 2003</b>	PRIORITY DATE CLAIMED: <b>October 1, 2002</b>
TITLE OF INVENTION: <b>MOUSE-ORIGIN PROTEINS FORMING DOMAIN OR USE THEREOF</b>		
APPLICANT(S) FOR DO/EO/US: <b>Takeshi MAEDA, Makoto INOUE, Takanori KIGAWA, Mikako SHIROUZU, Yoshihide HAYASHIZAKI, Shigeyuki YOKOYAMA, Tetsuo TAKAGI, Akiko TANAKA, Hiroshi HIROTA and Kazuhito SATOU</b>		
Applicant hereby submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <u>XX</u> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <u>  </u> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <u>XX</u> This is an express request to begin national examination procedures (35 USC 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <u>XX</u> The US has been elected (Article 31).</p> <p>5. <u>XX</u> A copy of the International Application as filed (35 U.S.C. 371(c)(2)):</p> <p>a. <u>  </u> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <u>XX</u> has been transmitted by the International Bureau.</p> <p>c. <u>  </u> is not required, as the application was filed in the United States Receiving Office (RO/US)</p> <p>6. <u>XX</u> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p>a. <u>XX</u> is attached hereto.</p> <p>b. <u>  </u> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <u>XX</u> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <u>  </u> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <u>  </u> have been transmitted by the International Bureau.</p> <p>c. <u>  </u> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <u>XX</u> have not been made and will not be made.</p> <p>8. <u>  </u> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <u>  </u> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <u>  </u> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>ITEMS 11. TO 20. BELOW CONCERN OTHER DOCUMENT(S) OR INFORMATION INCLUDED:</p> <p>11. <u>XX</u> An Information Disclosure Statement under 37 CFR 1.97 and 1.98 together with the international search report, PTO/SB/08</p> <p>12. <u>  </u> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. ASSIGNEE NAME AND ADDRESS: <b>RIKEN, Wako-shi, Japan</b> Please publish the assignee data with the application.</p> <p>13. <u>XX</u> A preliminary amendment.</p> <p>14. <u>  </u> An Application Data Sheet under 37 C.F.R. 1.76</p> <p>15. <u>  </u> A substitute specification.</p> <p>16. <u>  </u> A change of power of attorney and/or address letter.</p> <p>17. <u>XX</u> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.F.R. 1.821 - 1.825.</p> <p>18. <u>  </u> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <u>  </u> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <u>XX</u> Other items or information: 6 sheets of drawings.</p>		

U.S. APPLICATION NO. (if known) <b>90/529639</b>		INTERNATIONAL APPLICATION NO. PCT/JP2003/012575		DATE: March 31, 2005	
21. <u>XX</u> The following fees are submitted:				CALCULATIONS	PTO USE ONLY
Basic National Stage Fee				\$ 300.00	
National Stage Search Fee				\$ 500.00	
National Stage Examination Fee				\$ 200.00	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 1,000.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
TOTAL	46 -20 =	26	X \$ 50.00	\$1,300.00	
INDEPENDENT	3 - 3 =		X \$ 200.00		
Multiple dependent claims(s) (if applicable)			+ \$360.00	\$ 360.00	
TOTAL OF ABOVE CALCULATIONS =				\$2,790.00	
National Stage Application Size Fee-for each additional 50 sheets that exceeds 100 sheets \$ 250.00.				\$7,500.00	
Reduction by 1/2 for filing by small entity, if applicable. (Note 37 CFR 1.9, 1.27, 1.28).					
SUBTOTAL =				\$10,290.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)). +					
TOTAL NATIONAL FEE =				\$10,290.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					
TOTAL FEES ENCLOSED =				\$10,290.00	
				Amount to be:	
				refunded	\$
				charged	\$
<p>a. <u>XX</u> A check in the amount of \$10,290.00 to cover the above fees is enclosed. (\$300.00 for basic national stage fee; \$500.00 for national stage search fee; \$200.00 for national stage examination fee; \$130.00 for late filing of the declaration, \$1,300.00 for 26 additional claims; \$360.00 for multiple dependent claims and \$7,500.00 for pages exceeds 100 sheets).</p> <p>b. Please charge my Deposit Account No. 50-2866 in the amount of \$ to cover the above fees. (A duplicate copy of this sheet is enclosed.)</p> <p>c. <u>XX</u> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-2866.</p> <p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed to request that the application be restored to pending status.</p>					
Send All Correspondence To:			WESTERMAN, HATTORI, DANIELS & ADRIAN, LLP 1250 Connecticut Avenue, N.W. Suite 700 Washington, D.C. 20036 CUSTOMER No. 38834		
Typed or Printed Name: Scott M. Daniels			Reg. No.: 32,562		
Signature 			Date: March 31, 2005		

SMD/yap